Publication of Pricing Supplements

RNS Number : 4841Z
Barclays PLC
21 May 2021
 

Publication of Pricing Supplements

 

The following pricing supplements are available for viewing:

 

1.  Pricing Supplement in relation to Barclays PLC's issue of A$150,000,000 2.064 per cent. Fixed-to-Floating Rate Debt Instruments due May 2027 (the "Pricing Supplement 1");

2.  Pricing Supplement in relation to Barclays PLC's issue of A$250,000,000 Floating Rate Debt Instruments due May 2027 (the "Pricing Supplement 2"); and

 

3.  Pricing Supplement in relation to Barclays PLC's issue of A$200,000,000 3.382 per cent. Fixed-to-Floating Rate Debt Instruments due May 2032 (the "Pricing Supplement 3") (together the "Pricing Supplements"),

 

each issued under the Barclays PLC A$10,000,000,000 Debt Issuance Programme.

 

Please read the disclaimer below "Disclaimer - Intended Addressees" before attempting to access this service, as your right to do so is conditional upon complying with the requirements set out below.

 

To view Pricing Supplement 1, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/4841Z_1-2021-5-21.pdf

 

To view Pricing Supplement 2, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/4841Z_2-2021-5-21.pdf

 

To view Pricing Supplement 3, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/4841Z_3-2021-5-21.pdf

 

Copies of the above documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at:  https://data.fca.org.uk/#/nsm/nationalstoragemechanism  

 

For further information, please contact:

 

Barclays Treasury

1 Churchill Place

Canary Wharf

London E14 5HP

 

 

DISCLAIMER - INTENDED ADDRESSEES

 

IMPORTANT You must read the following before continuing: The following applies to the Pricing Supplements available by clicking on the links above, and you are therefore advised to read this carefully before reading, accessing or making any other use of the Pricing Supplements. In accessing the Pricing Supplements, you agree to be bound by the following terms and conditions, including any modifications to them, any time you receive any information from us as a result of such access.

The Pricing Supplements referred to above must be read in conjunction with the information memorandum dated 7 May 2021 (the "IM").

 

THE PRICING SUPPLEMENTS MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THE PRICING SUPPLEMENTS MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THE PRICING SUPPLEMENTS IN WHOLE OR IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.

NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION. ANY DEBT INSTRUMENTS ISSUED OR TO BE ISSUED PURSUANT TO THE PRICING SUPPLEMENTS AND THE IM HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER JURISDICTION. ANY DEBT INSTRUMENTS ISSUED OR TO BE ISSUED PURSUANT TO THE PRICING SUPPLEMENTS AND THE IM MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN AN OFFSHORE TRANSACTION TO A PERSON THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT.

Barclays PLC is not a bank or authorised deposit-taking institution which is authorised under the Banking Act 1959 (Commonwealth of Australia) ("Australian Banking Act"). The Debt Instruments are not obligations of the Australian Government or any other government and, in particular, are not guaranteed by the Commonwealth of Australia. Barclays PLC is not supervised by the Australian Prudential Regulation Authority. An investment in any Debt Instrument issued by Barclays PLC will not be covered by the depositor protection provisions in section 13A of the Australian Banking Act and will not be covered by the Australian Government's bank deposit guarantee (also commonly referred to as the Financial Claims Scheme). Debt Instruments that are offered for issue or sale or transferred in, or into, Australia are offered only in circumstances that would not require disclosure to investors under Parts 6D.2 or 7.9 of the Corporations Act 2001 of Australia and issued and transferred in compliance with the terms of the exemption from compliance with section 66 of the Australian Banking Act that is available to Barclays PLC.

Please note that the information contained in the Pricing Supplements and the IM referred to above may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplements and/or the IM) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplements and/or the IM is not addressed. Prior to relying on the information contained in thePricing Supplements and/or the IM you must ascertain from the Pricing Supplements and the IM whether or not you are part of the intended addressees of the information contained therein.

Confirmation of your Representation : In order to be eligible to view the Pricing Supplements or make an investment decision with respect to any Debt Instruments issued or to be issued pursuant to the Pricing Supplements, you must be a person other than a U.S. person (within the meaning of Regulation S under the Securities Act). By accessing the Pricing Supplements, you shall be deemed to have represented that you and any customers you represent are not U.S. persons, and that you consent to delivery of the Pricing Supplements via electronic publication.

You are reminded that the Pricing Supplements have been made available to you on the basis that you are a person into whose possession the Pricing Supplements may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not, nor are you authorised to, deliver the Pricing Supplements to any other person.

The Pricing Supplements do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the offering be made by a licensed broker or dealer and the underwriters or any affiliate of the underwriters is a licensed broker or dealer in that jurisdiction, the offering shall be deemed to be made by the underwriters or such affiliate on behalf of the issuer in such jurisdiction. Under no circumstances shall the Pricing Supplements constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of any Debt Instruments issued or to be issued pursuant to the Pricing Supplements, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Pricing Supplements have been made available to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the issuer, its advisers nor any person who controls any of them nor any director, officer, employee nor agent of it or affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the Pricing Supplements made available to you in electronic format and the hard copy versions available to you on request from the issuer.

Your right to access this service is conditional upon complying with the above requirement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPBXGDUCXDDGBB

Companies

Barclays (BARC)
UK 100

Latest directors dealings